| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS46001397 | BKPyv | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10003622 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10012046 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10008929 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10017508 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10017509 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10017510 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10017511 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10017512 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
| TVIS10021570 | HBV | ENSG00000151623.15 | protein_coding | NR3C2 | No | No | 4306 | B0ZBF6 P08235 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NR3C2 |
|---|---|
| DrugBank ID | DB04652 |
| Drug Name | Corticosterone |
| Target ID | BE0000668 |
| UniProt ID | P08235 |
| Regulation Type | |
| PubMed IDs | 10592235 |
| Citations | Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. |
| Groups | Experimental |
| Direct Classification | 21-hydroxysteroids |
| SMILES | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])[C@@]([H])(O)C[C@]12C)C(=O)CO |
| Pathways | Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency; Apparent Mineralocorticoid Excess Syndrome; Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH; 3-beta-Hydroxysteroid Dehydrogenase Deficiency; Corticosterone Methyl Oxidase I Deficiency (CMO I); 11-beta-Hydroxylase Deficiency (CYP11B1); Steroidogenesis; Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency; 17-alpha-Hydroxylase Deficiency (CYP17); Corticosterone Methyl Oxidase II Deficiency (CMO II); 21-Hydroxylase Deficiency (CYP21) |
| PharmGKB | |
| ChEMBL | CHEMBL110739 |
